After a Stroke, the Clock Ticks Louder

Three days ago, a man from a neighbouring building died. His name was Sasha.

Sasha worked in music production: helping artists get up on the big stage, arranging tours across the country, turning phone calls, venues, rehearsals and agreements into a working process. It wasn’t the glamorous side of the industry, where names become known overnight. It was the daily grind — calls, small venues, long drives, and the painstaking work of getting an artist in front of an audience.

His health had been shaky for a while. Last year, Sasha was diagnosed with a stroke, and disability status followed. Then came the life familiar to so many post-stroke patients: hospital, drips, medication, the daily fistful of tablets, the clinic, exhaustion, anxiety, and the nagging feeling that his body could no longer be trusted the way it used to be.

The illness reshaped his family too. His wife left. Sasha was raising his teenage son alone — a boy who’d just finished school with excellent results and was getting ready for university.

We’d run into each other now and then — in the courtyard, outside the clinic, in those ordinary little moments and corners where neighbours talk about blood pressure, sleep, nerves, doctors, prescriptions, and whatever the body no longer lets you ignore.

Yesterday, our neighbour from the residents’ committee called.

“Sasha’s gone,” he said. “We spoke to him three hours ago. Then he went into the kitchen, and his heart stopped.”

And today, in the courtyard, his children were going through his things in his car.

That’s how stroke statistics enter ordinary life. Not as a percentage. Not as a chart. As a car being emptied out by children who should never have had to do this so young.

Medically speaking, one phone call can’t establish that Sasha’s death was caused by his stroke — that would be jumping to conclusions. But medicine is quite clear about something else: after an ischaemic stroke, the danger doesn’t end the moment the patient walks out of hospital.

Stroke remains one of the leading causes of death and disability worldwide. In 2021, global stroke prevalence was estimated at 93.8 million people, with 11.9 million new strokes and 7.3 million stroke-related deaths that year. Ischaemic stroke is the most common type by far, accounting for around 65.3% of all cases.

But a stroke isn’t a single moment. It’s a sequence.

First, a vessel closes. Then a patch of brain is starved of oxygen and energy. Then the injury cascade kicks in — inflammation, excitotoxicity, oxidative stress, swelling, reperfusion injury. Some cells die fast. Others are left hanging — no longer healthy, but not yet irreversibly lost. It’s in that narrow window that treatment can still change how it all ends.

Modern medicine has made real headway on the first half of that sequence. Thrombolytics can dissolve clots. Mechanical thrombectomy can remove them. Stroke units, emergency care and well-run hospital routes have saved plenty of lives and cut down on disability.

But reopening a vessel isn’t the same as saving the brain.

And leaving hospital isn’t the same as recovering.

After a stroke, a person stays at risk medically. A large Japanese national study of 18,719 patients with non-cardioembolic ischaemic stroke or transient ischaemic attack found a recurrent ischaemic stroke rate of 103.5 events per 1,000 patient-years. After a first recurrence, the risk climbed even higher: the rate of a further ischaemic stroke reached 199.9 per 1,000 patient-years, death 53.3, myocardial infarction or unstable angina 39.6. Time to death was shorter after recurrence too — a median of 255 days, against 366 days after the first event. And only 54.2% of patients had received any antithrombotic therapy at all in the 90 days before their first recurrence.

These numbers matter for more than their own sake. What they really show is this: after a first stroke, a person doesn’t step out of danger — they step into a new vascular reality, where recurrence, bleeding risk, other conditions, weakening treatment effectiveness and general physical exhaustion all become part of the same risk.

For the patient, that can look like weakness, memory trouble, medication, rehabilitation, fear of it happening again, lost work, lost independence — and a quiet fear running through the family, flinching at every unexpected phone call.

But there are treatments. The question isn’t only how to reopen a blocked vessel — it’s how to protect vulnerable nerve tissue, limit the damage that follows, and improve the odds that someone comes back with less disability.

That’s exactly where VOSTOK ONE and its Scientific Team have focused their work, developing VO-IS01 — a promising candidate for ischaemic stroke. It is a pre-IND-enabling therapeutic programme preparing for preclinical development under applicable GxP requirements; GLP will apply to the relevant nonclinical safety studies. At the heart of the work is a narrower, more testable question: can a therapeutic intervention be built that protects vulnerable brain tissue during or after acute ischaemic injury — before temporary damage turns into permanent disability?

Developing stroke drugs is hard. The treatment window is short. Patients don’t fit neatly into one category. Trial design has to account for timeframes, when treatment starts, stroke severity, standard care, and unforgiving functional endpoints — the modified Rankin Scale at 90 days, for one. Safety demands are especially high, above all around bleeding and vascular risk.

There’s real progress in this space. Pharmaceutical interest in stroke neuroprotection is growing wherever there’s precise biotechnology and a testable rationale behind the science. For VOSTOK ONE, VO-IS01 isn’t a comment on a big medical problem — it’s a potentially licensable pharmaceutical asset in an area where the need for treatment stays high, and the cost of getting it wrong isn’t measured in money.

There’s no happy ending to this story. No recovery arc, no scan showing years of stability, no closing shot of triumph. There’s a death at 56 — and a reminder that a long life isn’t handed to you by default. It’s a biological problem you have to fight for — through prevention, treatment, precision medicine, and research that should one day give doctors more options than they have now.

For VOSTOK ONE, stories like this don’t prove anything scientifically. They don’t replace data. They don’t make a molecule work.

But they remind everyone why this work is being done in the first place. We all hope to live to a ripe old age — maybe even a hundred. But life has its own plans for us. Sasha was only 56, and today his children were going through his things in his car in the courtyard. Perhaps his story, and the memory of him, is one more reason for this team to keep pushing forward in the research on treating and preventing ischaemic stroke.